Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. develops precision genetic medicines through a base-editing platform that combines gene editing, delivery and internal manufacturing capabilities. News about Beam Therapeutics centers on clinical and business updates for risto-cel in sickle cell disease, BEAM-302 in alpha-1 antitrypsin deficiency, liver-targeted genetic disease programs such as BEAM-304 in phenylketonuria and BEAM-301 in GSDIa, and financing activity tied to late-stage development.
Company updates also cover financial results, portfolio prioritization, published clinical data, FDA designations and regulatory interactions, licensing arrangements for base-editing patent rights, and governance changes.
Beam Therapeutics Inc. (Nasdaq: BEAM) reported significant advancements in its genetic medicine programs, showcasing a more than four-fold increase in circulating levels of functional protein for Alpha-1 Antitrypsin Deficiency. The company also demonstrated over 80% direct correction in sickle cell disease and greater than 90% editing in its fetal hemoglobin program. Financially, Beam holds $253.4 million in cash as of March 31, 2020, with R&D expenses rising to $21.5 million. The net loss for Q1 2020 was $31.7 million, or $1.03 per share, an increase from the previous year.
Summary not available.
Summary not available.